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Objectives We evaluated the efficacy and safety of the percutaneous ventricular assist device (pVAD) in patients in se-
vere refractory cardiogenic shock (SRCS) despite intra-aortic balloon pump (IABP) and/or high-dose vaso-
pressor support.
Background SRCS is associated with substantial mortality despite IABP counterpulsation. Until recently, there was no rapid,
minimally invasive means of providing increased hemodynamic support in SRCS.
Methods A total of 117 patients with SRCS implanted with TandemHeart pVAD (CardiacAssist, Inc., Pittsburgh, Pennsylva-
nia) were studied, of whom 56 patients (47.9%) underwent active cardiopulmonary resuscitation immediately
before or at the time of implantation. Data was collected regarding clinical characteristics, hemodynamics, and
laboratory values.
Results Eighty patients had ischemic and 37 patients had nonischemic cardiomyopathy. The average duration of support
was 5.8  4.75 days. After implantation, the cardiac index improved from median 0.52 (interquartile range
[IQR]: 0.8) l/(min·m2) to 3.0 (IQR: 0.9) l/(min·m2) (p  0.001). The systolic blood pressure and mixed venous
oxygen saturation increased from 75 (IQR: 15) mm Hg to 100 (IQR: 15) mm Hg (p  0.001) and 49 (IQR: 11.5)
to 69.3 (IQR: 10) (p  0.001), respectively. The urine output increased from 70.7 (IQR: 70) ml/day to 1,200
(IQR: 1,620) ml/day (p  0.001). The pulmonary capillary wedge pressure, lactic acid level, and creatinine level
decreased, respectively, from 31.53  10.2 mm Hg to 17.29  10.82 mm Hg (p  0.001), 24.5 (IQR: 74.25)
mg/dl to 11 (IQR: 92) mg/dl (p  0.001), and 1.5 (IQR: 0.95) mg/dl to 1.2 (IQR: 0.9) mg/dl (p  0.009). The
mortality rates at 30 days and 6 months were 40.2% and 45.3%, respectively.
Conclusions The pVAD rapidly reversed the terminal hemodynamic compromise seen in patients with SRCS refractory to
IABP and vasopressor support. (J Am Coll Cardiol 2011;57:688–96) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.613In patients with ischemic cardiomyopathy (ICM) and car-
diogenic shock, the mortality rate ranges from 55% to 73%
despite intra-aortic balloon pump (IABP) counterpulsation
and coronary reperfusion (1–5). Patients with nonischemic
cardiomyopathy (NICM) and cardiogenic shock are also at
increased risk for cardiovascular death (6), although this
increase is not as well documented. For patients with either
ICM or NICM and cardiogenic shock, prompt reversal of
hypoperfusion is essential to support organ function during
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accepted August 17, 2010.post-treatment myocardial recovery and to stabilize the
patient for definitive percutaneous or surgical intervention.
Although various pharmacological and mechanical meth-
ods are available for maintaining hemodynamic support in
patients with severely depressed left ventricular function, all
of these methods have their limitations. The most com-
monly used form of support is IABP counterpulsation.
However, the IABP is often inadequate to reverse hemo-
dynamic compromise in patients with severe refractory
cardiogenic shock (SRCS). In patients presenting with
SRCS, the mortality rate ranges from 52% to 76% (7–9).
See page 697
Although complete hemodynamic support is possible
with surgically placed systems such as cardiopulmonary
support devices and left ventricular assist devices (LVADs),
these are themselves associated with significant morbidity
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ventricular assist device (pVAD) (CardiacAssist, Inc., Pitts-
burgh, Pennsylvania), a minimally invasive, continuous-flow
device capable of complete hemodynamic support, is available.
The TandemHeart pVAD can be inserted quickly, in the
catheterization laboratory, to provide temporary mechanical
circulatory support until more definitive therapies can be
pursued.
In light of the high mortality rate of cardiogenic shock
patients and the limitations of the IABP, we sought to
determine the efficacy of the pVAD for hemodynamic support
in patients with ICM or NICM that was refractory to IABP
and pressor support.
Patient Baseline CharacteristicsTable 1 Patient Baseline Characteristics
Total patients, n 117
Age, yrs 55.37 15.576
Male sex 80 (68.4%)
Left ventricular ejection fraction 20 (IQR: 5)
Vasopressors, n 2.1 1.2
Ischemic cardiomyopathy 80 (68.4%)
STEMI 48 (60%)
NSTEMI 32 (40%)
Previous myocardial infarction 64 (80%)
Previous PCI/ACB 64 (80%)
No. of vessels with occlusive CAD 2.6
Diabetes mellitus 33 (41.2%)
Hypertension 54 (67.5%)
Hyperlipidemia 54 (67.5%)
Chronic kidney disease 40 (50%)
Current or former smoker 38 (47.5%)
Previous CVA/TIA 7 (8.8%)
Peripheral vascular disease 16 (20%)
Nonischemic cardiomyopathy 37 (31.6%)
Idiopathic dilated cardiomyopathy 10 (27.27%)
Myocarditis 9 (24.32%)
Valvular diseases 7(18.91)
Grade 2R orthotopic heart transplant rejection 3 (8.1%)
Restrictive cardiomyopathy 3 (8.1%)
Peripartum cardiomyopathy 1 (2.7%)
Sarcoid cardiomyopathy 1 (2.7%)
Alcoholic cardiomyopathy 1 (2.7%)
Tako-tsubo cardiomyopathy 1 (2.7%)
Angiosarcoma 1 (2.7%)
Intra-aortic balloon pump 96 (82.1%)
Ischemic cardiomyopathy 69/80 (86.2%)
Nonischemic cardiomyopathy 27/37 (73%)
Undergoing CPR 56 (47.9%)
Ischemic cardiomyopathy 41/80 (51.2%)
Nonischemic cardiomyopathy 15/37 (40.5%)
Mechanical ventilation 54 (46.2%)
AICD 39 (33.3%)
Data are n (%) unless otherwise stated.
ACB  aortocoronary bypass; AICD  automated implantable cardioverter-defibrillator; CAD 
coronary artery disease; CPR  cardiopulmonary resuscitation; CVA  cerebrovascular accident;
NSTEMI  non–ST-segment elevation myocardial infarction; PCI  percutaneous coronary inter-
vention; STEMI  ST-segment elevation myocardial infarction; TIA  transient ischemic attack.Methods
From May 2003 through No-
vember 2008, 117 consecutive
patients with either ICM or
NICM and SRCS received
pVADs (Table 1). This included
80 men and 37 women with an
average age of 55.37  15.6 years.
Eighty patients had ICM, and
37 had NICM. The median initial
left ventricular ejection fraction
for the 2 groups was 20.5% (in-
terquartile range [IQR]: 5%) and
36% (IQR: 25%), respectively.
All patients were categorized
as having either ICM or NICM
based on presence or absence of
occlusive disease on cardiac cath-
eterization (Fig. 1). We catego-
rized patients in the ICM group
if they had a history of a previous
myocardial infarction secondary
to occlusive coronary artery dis-
ease (CAD), previous percutane-
ous or surgical revascularization, or evidence of occlusive
CAD during cardiac catheterization at the time of cardio-
genic shock. Patients whose catheterization studies were
negative for occlusive CAD were assigned to the NICM
group. Only 5 of 80 patients in the ICM group were
undergoing active ST-segment elevation myocardial infarc-
tion (STEMI) at the time of implantation and included
patients with severe complications such as post-infarct
ventricular septal defect, incessant ventricular tachycardia
(VT) storm, and primary pump failure. All other patients
had chronic ICM/NICM.
All hemodynamic (except pVAD flow rate) and bio-
chemical parameters post-implantation were measured at
24 h after implantation or last available biochemical param-
eters in case of death before 24 h after implantation. Flow
rates were measured at 1 h after implantation.
The ICM group comprised 61 men and 19 women with
an average age of 61.8  11.0 years. Forty-eight patients
(60%) had previously been diagnosed with STEMI, and 32
patients (40%) had been diagnosed with non–ST-segment
elevation myocardial infarction. Most patients (64 of 80;
80.0%) had previously revascularized CAD, including left
main disease; angiography showed an average of 2.6 in-
volved vessels that needed intervention.
The NICM group was composed of 19 men and 18
women with an average age of 41.4  14.8 years and
predominantly dilated cardiomyopathy (10 of 37; 27%) and
myocarditis (9 of 37; 24.3%).
SRCS was characterized by a systolic blood pressure of
90 mm Hg, a cardiac index of 2.0 l/(min·m2) and
Abbreviations
and Acronyms
CAD  coronary artery
disease
CPR  cardiopulmonary
resuscitation
IABP  intra-aortic balloon
pump
ICM  ischemic
cardiomyopathy
IQR  interquartile range
LVAD  left ventricular
assist device
MAP  mean arterial
pressure
NICM  nonischemic
cardiomyopathy
pVAD  percutaneous
ventricular assist device
SRCS  severe refractory
cardiogenic shock
STEMI  ST-segment
elevation myocardial
infarctionevidence of end-organ failure despite IABP/pressor support.
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Percutaneous VAD in Severe Cardiogenic Shock February 8, 2011:688–96Informed consent was obtained from the surrogate decision
makers of all the patients studied. We prospectively col-
lected data regarding clinical factors and characteristics,
hemodynamic values, laboratory values, medications, and
diagnostic tests. Post-hospitalization follow-up information
was obtained for all patients for at least 6 months after
pVAD placement. As in previous studies (13–15), the
following values were imputed to patients who were under-
going active cardiopulmonary resuscitation: a cardiac index
of 0 l/(min·m2), systolic blood pressure of 60 mm Hg, and
diastolic blood pressure of 20 mm Hg. This was done to
highlight adequacy of manual compressions to maintain
cerebral perfusion.
The TandemHeart and its method of implantation have
been described elsewhere (16). Briefly, the TandemHeart is
a continuous-flow pump that can be inserted percutane-
ously, in the cardiac catheterization laboratory. All devices
are inserted by a board-certified interventional cardiologist.
A 21-F left atrial cannula, inserted by means of a venous
trans-septal puncture via the femoral vein, channels blood
into the pump, and a 15- to 17-F femoral artery cannula
carries the blood to the systemic arterial circulation. The
size of the outflow cannula is selected after peripheral
angiography. The TandemHeart is capable of up to 4.5
l/min of assisted cardiac output. Heparin is administered
continuously to achieve a targeted activated partial throm-
boplastin time of 60 to 80 s.
In our center, patients with cardiogenic shock are placed
on escalating doses of vasopressors (dopamine, norepineph-
rine, vasopressin, epinephrine, phenylephrine) to maintain
viable hemodynamic status. The choice of vasopressors was
tailored for each patient depending on their rapidly chang-
ing hemodynamic status as well as the initial vasopressor
regimen before transfer to our center. Patients not stabilized
on low-dose vasopressors are transitioned onto an IABP
followed by high-dose vasopressors. Patients with SRCS
despite high-dose vasopressors and IABP were transitioned
to the pVAD. A few patients with severe cardiovascular
Figure 1 Overall Study Design and Results
A total of 117 patients (80 with ischemic and 37 with nonischemic cardiomyopath
percutaneous ventricular assist device (pVAD).complications like post-infarct ventricular septal defect with iunstable hemodynamics/incessant VT storm were directly
transitioned to pVAD. Almost all the patient were on
systemic anticoagulation as well as diuretics. Patients requir-
ing right ventricular support were supported with milri-
none/dobutamine/epoprostenol sodium. Figure 2 highlights
he strategy used in acute cardiopulmonary failure at our
nstitute.
Patients were weaned off TandemHeart pVAD based on
erial real-time assessment of their hemodynamics and
nd-organ function. The pVAD flow rate was constantly
djusted to maintain mixed venous oxygen saturation 70
nd mean arterial pressure (MAP) 60 mm Hg and to
acilitate aortic valve opening. Patients showing adequate
emodynamics and improving end-organ function at
VAD flow rate of 2 l/day for 2 days were gradually weaned
ff the pVAD. Those who did not meet the above criteria
ere transitioned to LVAD/transplant. The decision to
ridge to LVAD/transplant/recovery was based on several
actors, including post-device placement course, complica-
ions, hemodynamic status, and overall suitability as a
andidate for LVAD/transplant.
In this study, mean values and SDs for continuous
ariables were determined with SPSS version 18 (SPSS Inc.,
hicago, Illinois). A p value 0.05 was considered signif-
cant. Categorical variables were presented and compared as
umbers and percentages. The distribution of all variables
as tested for normality, and nonparametric testing was
one to analyze them. All skewed parameters have been
epresented by median and IQR, whereas all nonskewed
arameters have been described as mean  SD. Paired t
ests were used for analysis between continuous nonskewed
ariables and nonparametric testing using medians for
kewed variables. Univariate and multivariate analysis was
one using logistic regression between survivors and non-
urvivors and was adjusted for age, IABP, pre-implantation
ardiopulmonary resuscitation (CPR), pre-implantation
reatinine, pre-implantation pressor use, and pre-
severe refractory cardiogenic shock were implanted with TandemHearty) withmplantation MAP. Kaplan-Meier survival analysis was
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myopathy and treatment arm.
Results
In the overall group, 96 patients (82.1%) were receiving
IABP support before pVAD placement. The 21 patients (11
with ICM, 10 with NICM) who did not undergo IABP
counterpulsation required continuous CPR (average cardiac
index, 0 l/[min·m2]) and were deemed beyond hemodynamic
salvage with the addition of IABP support alone, so pVADs
were emergently placed. Fifty-six (47.9%) of the 117 patients
(41 of 80 [51.2%] with ICM; 15 of 37 [40.5%] with NICM)
were undergoing CPR during pVAD placement.
Figure 2 Strategy for Acute Cardiopulmonary Failure: Texas He
This reflects the strategy for acute cardiopulmonary failure at our center. Decision
nary failure as well as right ventricular (RV)/left ventricular (LV)/biventricular (BI
percutaneous left ventricular assist device; pRVAD  percutaneous right ventricula
Hemodynamic and Biochemical Values in All PaTable 2 Hemodynamic and Biochemical Val
Value Pre
Cardiac index, l/(min·m2) 0.52 (
SBP, mm Hg 75 (
DBP, mm Hg 30 (
MAP, mm Hg 45 (
HR, beats/min 105.1
SVO2, % 49 (
PCWP, mm Hg 31.52
Pulmonary arterial pressure, mm Hg 39.16
Lactic acid, mg/dl 24.5 (
LDH, U/dl 602 (
pH 7.22
Creatinine, mg/dl 1.5 (
BUN, mg/dl 39.72
Urine output, ml/day 70.3 (
Hemoglobin 11 (
AST 125 (
ALT 75 (
Interquartile range values are in parentheses.
ALT  alanine transaminase; AST  aspartate transaminase; BUNLDH  lactate dehydrogenase; MAP  mean arterial pressure; PCWP  pu
assist device; SBP  systolic blood pressure; SVO2  mixed venous oxygen sThe reason for initiating CPR was pulseless VT in 50%,
ventricular fibrillation in 27.8%, pulseless electrical activity
in 14.8%, bradycardic arrest in 5.55%, and asystole in 1.8%.
All of the arrests occurred before the device was implanted.
Some of them were in the field before the patients were
airlifted to our facility; others were in the emergency room,
critical care unit, and catheterization lab. The average time
from CPR onset to TandemHeart implantation was 65.6 
41.3 min. On an average it took 15 to 65 min to implant the
TandemHeart. After device placement the decision to
transition to LVAD was based on several factors, including
post-device placement course, complications, hemodynamic
status, and overall suitability as a candidate for LVAD.
stitute Experience
ing the type of device to be used is based on cardiac/pulmonary/cardiopulmo-
ure. ECMO  extracorporeal membrane oxygenation; LA  left atrial; pLVAD 
st device; V-A  venoatrial; V-V  venovenous.
in Cardiogenic ShockAll Patients in Cardiogenic Shock
With pVAD p Value
3.0 (0.9) 0.001
100 (15) 0.001
65 (20) 0.001
81 (15) 0.001
85.7 12.9 0.001
69.29 (10) 0.001
0 17.29 10.82 0.001
0 26.70 7.99 0.001
) 11.0 (12) 0.001
416.5 (335) 0.101
4 7.44 0.06 0.001
1.2 (0.9) 0.009
8 30.35 15.54 0.108
1200 (1620) 0.001
10.25 (1.8) 0.001
5) 75 (169) 0.02
55.5 (316.75) 0.06
od urea nitrogen; DBP  diastolic blood pressure; HR  heart rate;art In
regard
V) fail
r assitientsues in
-pVAD
0.8)
15)
20)
20)
 18.0
11.5)
 10.2
 12.1
74.25
630)
 0.1
0.95)
 17.8
70)
2.65)
363.7
317)
 blo
lmonary capillary wedge pressure; pVAD  percutaneous ventricular
aturation.
E
o
c
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insult/stroke, of which three had the pVAD replaced (1
with another pVAD, 1 with Levitronix and 1 with Heart-
mate II LVAD) and later survived to discharge. Thirty one
patients had multi organ failure after device placement, of
which fourteen survived to discharge, with three undergoing
transplantation, and four being transitioned to other
LVAD’s (Levitronix, HeartMate XVE, HeartMate II, Ex-
tra Corporeal Membrane Oxygenator). The other 17 of 31
patients with multiorgan failure died.
The average number of pressor agents used was 2.1 1.2.
ach agent was titrated to maximal dosing before initiation
f additional vasopressors. The mean time from the onset of
ardiogenic shock to placement of a pVAD was 2.6  3.0
days in both the ICM and NICM groups. The average
duration of pVAD support was 5.8  4.75 days. The
average pVAD flow rate was 3.29  0.7 l/min at 1 h after
implantation.
Hemodynamic and biochemical values. There was signif-
icant improvement in all hemodynamic values, an increase
in mixed venous oxygen saturation and urine output, and a
concurrent decline in creatinine and blood urea nitrogen
levels in the overall cohort after implantation of the pVAD
(Table 2). Similar improvements in hemodynamic and
biochemical values were also seen separately in both the
ICM and NICM groups (Table 3). There was a significant
decrease in the lactic acid level, both overall and within each
group.
In-hospital treatment and outcomes. Thirteen patients
underwent percutaneous or surgical revascularization.
Thirty-one patients went on to LVAD placement, and 5
Hemodynamic and Biochemical Values in ICM and NICM Patients iTable 3 Hemodynamic and Biochemical Values in ICM and NIC
Value
Ischemic Cardiomyop
Pre-pVAD With pVAD
CI, l/min·m2 0.4 (0.7) 2.8 (0.5
SBP, mm Hg 80 (20) 100 (20)
DBP, mm Hg 30 (20) 70 (15)
MAP, mm Hg 40 (32) 82.5 (15)
HR, beats/min 102.9 21.5 84.6 11
SVO2, % 45 (13) 69 (13)
PCWP, mm Hg 29.81 10.27 16.0 6
Pulmonary arterial pressure, mm Hg 39.86 14.46 26.5 8.7
Lactic acid, mg/dl 24 (66) 11(9)
LDH, U/dl 546 (692) 421 (383
pH 7.23 0.15 7.46 0.6
Creatinine, mg/dl 1.5 (1.15) 1.3 (0.9
BUN, mg/dl 37.08 15.59 31.27 14
Urine output, ml/day 62 (64.5) 1,150 (800
EF, % 20 (5) 36 (28)
Hemoglobin, g/dl 10.9 (2.8) 10.1 (1.8
AST 141 (360) 66 (132
ALT 75 (266) 51 (106
Interquartile range values are in parentheses.
CI  cardiac index; DBP  diastolic blood pressure; EF  ejection fraction; ICM  ischemic car
as in Table 2.patients underwent orthotopic heart transplantation; theremaining patients were treated medically. The total mor-
tality rate was 40.2% at 30 days and 45.3% at 6 months. In
the ICM group, the 30-day and 6-month mortality rates
were 43.8% and 50%, respectively. Mortality rates in the
NICM group were 32% and 35% at 30 days and 6 months,
respectively. Twenty-four (43%) of the 56 patients who had
undergone resuscitation during pVAD placement were alive
at 30 days, and 21 (36.5%) were alive at 6 months.
Twenty-four patients (50%) who presented with STEMI in
the ICM group were alive at 30 days, and 21 (44.75%) were
alive at 6 months. Twenty-four of the 31 patients (77.4%)
who received an LVAD were alive at 30 days, and 21
patients (67.7%) were alive at 6 months. The Kaplan-
Meier survival curves for the overall group (Fig. 3), ICM
versus NICM (Fig. 4), and stratified by treatment sub-
group (Fig. 5) are provided.
Safety and efficacy. Complications included 1 wire-
mediated perforation of the left atrium. The device was
successfully implanted, and the patient underwent emergent
surgical repair while the pVAD provided left atrial unload-
ing and hemodynamic support, but the patient later died of
post-operative complications. Another patient had a right
common femoral artery dissection that required surgical
repair. Groin hematomas occurred in 6 patients (5.12%) and
bleeding around cannula site occurred in 34 of 117 patients
(29.05%), whereas device-related limb ischemia was seen in
4 patients (3.41%). The post-implantation course was com-
plicated by sepsis/systemic inflammatory response syndrome
in 29.9%, gastrointestinal bleeding in 19.65%, coagulopathy
in 11%, and stroke in 6.8% of patients. Blood transfusions
diogenic Shocktients in Cardiogenic Shock
Nonischemic Cardiomyopathy
p Value Pre-pVAD With pVAD p Value
0.001 0.7 (0.9) 3.9 (1.87) 0.001
0.001 75 (15) 100 (15) 0.001
0.001 35 (15) 65 (20) 0.003
0.001 55 (15) 80.5 (10) 0.001
0.002 108.6 10.9 88.2 14.6 0.001
0.002 53 (10) 70 (14) 0.05
0.001 33.18 10.09 18.38 13.85 0.001
0.007 38.43 9.33 28.12 8.34 0.011
0.001 36 (83) 14 (8.5) 0.05
0.229 627 (697) 384 (290) 0.089
0.001 7.21 0.14 7.42 0.7 0.003
0.111 1.6 (0.9) 1.15 (0.85 0.024
0.37 45.0 22.42 28.67 17.86 0.19
0.001 74.5 65.0 1,390 870 0.001
0.001 20 (6) 30 (25) 0.08
0.058 11 (2.5) 10.5 (2.6) 0.04
0.023 100 (646) 68 (367) 0.211
0.110 85 (667) 49.5 (363) 0.309
pathy; NICM  nonischemic cardiomyopathy; SBP  systolic blood pressure; other abbreviationsn CarM Pa
athy
)
.3
8
)
5
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.95
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)were needed in 70 patients (57 of 80 [71%] patients with
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the safety of the device are listed in Table 4.
Analysis of survivors and nonsurvivors. After pVAD
placement, survivors had significant improvement in all
hemodynamic and most biochemical values, including lactic
acid, whereas nonsurvivors had no significant decrease in
lactic acid despite significant improvement in hemodynamic
values. Nonsurvivors were older (p  0.013), had higher
rates of CPR (p  0.001), and were on a higher number of
asopressors after implantation (p 0.07) as compared with
he survivors. Survivors showed a significant improvement
n pulmonary capillary wedge pressure, lactic acid, and
jection fraction between pre- and post-implantation values
s compared with nonsurvivors. In a univariate analysis of
Figure 5 Survival Analysis Stratified by Bridge to Transplant,
Bridge to LVAD, and Bridge to Recovery
Kaplan-Meier survival curve stratified by treatment showing best outcomes for
bridge to transplant, followed by bridge to left ventricular assist device (LVAD)
and bridge to recovery.
Safety and Efficacy of Use of Tandem HeartPercutaneous Ventricular Assist D vice:Complication Rate in Ou Center
Table 4
Saf ty and Efficacy of Use of Tandem Heart
Percutaneous Ventricular Assist Device:
Complication Rate in Our Center
Adverse Event Frequency %
Groin hematoma 6/117 5.12
Limb ischemia 4/117 3.41
Bleeding around cannula site 34/117 29.05
Femoral artery dissection 1/117 0.85
Atrial perforation 1/117 0.85
Sepsis 35/117 29.90
Coagulopathy 13/117 11.00
Stroke 8/117 6.83
Blood transfusions 70/117 59.80Figure 3 Survival Analysis of All Patients
Kaplan-Meier survival curve of 117 patients showing survival at 30 days,
6 months, and last follow-up.Figure 4 Survival Analysis Stratified by Ischemic and
Nonischemic Cardiomyopathy
Kaplan-Meier survival curve for ischemic and nonischemic cardiomyopathy showing
better survival in nonischemic cardiomyopathy as compared with ischemic
cardiomyopathy. Gastrointestinal bleed 23/117 19.65
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parameters before implantation, age, IABP use, and CPR
were found to have a statistically significant difference
Differences in Baseline ParametersBetw en Survivor a d NonsurvivorsTable 5 D fferences in Baseline ParametersBetween Survivors and Nonsurvivors
Parameters Survivors Nonsurvivors p Value
Age, yrs 52.33 15.6 59.32 14.47 0.013
pVAD flow rate 3.39 0.63 3.12 0.86 0.262
ICM 41/64 (64%) 40/53 (75%) 0.229
NICM 23/64 (35.9%) 13/53 (24.5%) 0.299
Male 41/64 (64%) 40/53 (75.5%) 0.229
IABP 48/75 (75%) 48/53 (90.6%) 0.032
CPR 20/64 (31.3%) 36/53 (67.9%) 0.001
Mechanical ventilation 32/64 (50%) 21/53 (39.6%) 0.448
Pacemaker 23/64 (35.9%) 16/53 (31%) 0.69
Pressors before pVAD
placement
1.9 1.24 2.3 1.28 0.136
Pressors after pVAD
placement
1.25 1.00 1.58 1.12 0.07
Groin complications 7/64 (10.9%) 4/53 (7.5%) 0.75
SIRS 16/64 (25%) 19/53 (36.8%) 0.22
Stroke after LVAD 2/64 (3.125%) 6/53 (11.3%) 0.14
Diabetes 22/64 (34%) 17/53 (32.1%) 0.90
Hypertension 30/64 (47%) 35/53 (66%) 0.038
Hyperlipidemia 21/64 (32.8%) 23/53 (43.39%) 0.25
Peripheral vascular disease 8/64 (12.5%) 9/53 (16.9%) 0.39
Stroke before LVAD 5/64 (7.8%) 5/53 (9.4%) 0.49
Atrial fibrillation 11/64 (17.2%) 4/53 (7.5%) 0.167
Chronic kidney disease 25/64 (39%) 22/53 (41.5%) 0.84
Obstructive sleep apnea 8/64 (12.5%) 5/53 (9.4%) 0.76
Smoking 31/64 (48.4%) 14/53 (26.5%) 0.65
Alcohol 11/64 (17.2%) 6/53 (11.3%) 0.41
Drug abuse 2/64 (2.1%) 1/53 (2.0%) 0.90
Values are mean  SD or n (%).
CPR  cardiopulmonary resuscitation; IABP  intra-aortic balloon pump; ICD  ischemic
cardiomyopathy; LVAD  left ventricular assist device; NICM  nonischemic cardiomyopathy;
pVAD  percutaneous ventricular assist device.
Comparison of Survivors and NonsurvivorsTable 6 Comparison of Survivors and Nonsurvivors
Value
Survivors
Pre-pVAD With pVAD
CI, l/(min·m2) 0.8 (0.9) 3.28 (0.57)
SBP, mm Hg 80 (15) 105 (10)
DBP, mm Hg 35 (15) 70 (15)
MAP 60 (34) 82 (12)
SVO2, % 49 123 70 15
PCWP, mm Hg 33.71 9.06 16.53 10.35
PAP, mm Hg 40.82 12.84 27.44 8.30
Lactic acid, mg/dl 24 36 10 6
Cr, mg/dl 1.5 0.9 1.2 0.7
BUN, mg/dl 34.12 17.79 28.43 15.86
Urine output, ml/day 75 60 1,420 1,000
EF, % 20 (5) 40 (20)
Hemoglobin 11.8 (2.9) 9.9 (1.5)
AST 81.5 (297) 48 (37.5)
ALT 51 (252) 32 (62)Interquartile range values are in parentheses.
Cr  creatinine; MAP  mean arterial pressure; PAP  pulmonary artery pressure; other abbreviationbetween survivors and nonsurvivors (Tables 5, 6, and 7). In
a multivariate analysis of survivors versus nonsurvivors,
pre-implantation CPR (hazard ratio 4.54; p 0.04) was the
single most important and significant risk factor after
adjusting for age, IABP, MAP, creatinine, and pre-
implantation pressors (Table 8).
Discussion
So far, few researchers have evaluated patients with SRCS
because of the difficulty in randomizing this extremely
high-risk group. Recently, Anderson et al. (17) presented
data about the AB5000 (ABIOMED Inc., Danvers, Mas-
sachusetts), a surgically placed LVAD used for temporary
support in patients with SRCS. Most (87%) of Anderson’s
patients were receiving IABP and vasopressor support
before device implantation, and their baseline hemodynamic
values were better than equivalent values in our study.
However, the in-hospital (30-day) mortality rate was also
higher in Anderson’s patients than in ours (54% vs. 40.2%).
Studies evaluating cardiopulmonary support for patients
with SRCS have had a high (67%) 30-day mortality rate, as
well as a high rate of severe vascular complications (18,19).
Although the SHOCK (Early Revascularization in Acute
Myocardial Infarction Complicated by Cardiogenic Shock)
trial did not study patients with SRCS, it was the largest
and most influential randomized trial to date that has
evaluated patients in cardiogenic shock. In comparison with
patients in the SHOCK trial, our patients had a lower
30-day in-hospital mortality rate (40.2 % vs. 47%), despite
the fact that they presented with SRCS (20). Our ICM
patients had worse baseline hemodynamic values than pa-
tients in the SHOCK trial: a lower left ventricular ejection
fraction (23.43 11.52% vs. 29.1 10.6%), a lower cardiac
ndex (0.36  0.7 l/[min·m2] vs. 1.8  0.7 l/[min·m2]),
Nonsurvivors
Value Pre-pVAD With pVAD p Value
0.001 0.21 (0.56) 2.52 (1.20) 0.001
0.001 68.0 (12) 100 (14) 0.001
0.001 30 (10) 60 (15) 0.001
0.009 33 (20) 80 (15) 0.001
0.001 45 12 69.4 11.6 0.008
0.001 29.06 13.27 21.33 12.22 0.22
0.001 36.07 10.28 24.17 6.94 0.01
0.001 61 115 16 58 0.053
0.015 1.65 1.77 1.4 0.85 0.04
0.52 42.22 17.65 31.44 17.0 0.19
0.001 73.91 65.6 1,000 650 0.019
0.001 22 (11.5) 28.5 (28) 0.064
0.001 10.7 (2.8) 10.6 (2) 0.692
0.120 234 (355) 129 (580) 0.286
0.068 137.5 (347) 106 (404) 0.591p









s in Table 3.
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89.0  22.8 mm Hg), and a higher pulmonary capillary
edge pressure (29.8  10.27 mm Hg vs. 24  7 mm Hg),
yet they had a lower 30-day mortality (20). In addition,
51.2% of our ICM patients were undergoing resuscitation at
the time of pVAD placement, and 43% of this group
survived to 30 days. Moreover, our ICM patients had a
higher incidence of previous myocardial infarction (80% vs.
40%), previous revascularization (80% vs. 17%), and under-
lying renal insufficiency (50% vs. 11%) (20).
Compared with the medically treated patients in the
SHOCK trial (30-day mortality, 56%), our ICM patients
who received a pVAD and were not considered suitable
candidates for subsequent revascularization or LVAD im-
plantation had a 30-day mortality rate of 100% (20). This
difference in mortality further illustrates how critically ill our
patients were. The significant mortality rates of patients in
both studies who were treated only with medical therapy
emphasizes the need for subsequent revascularization or
LVAD placement to significantly improve the survival of
ICM patients who present in cardiogenic shock; this finding
is consistent with observational data from the SHOCK trial
registry and the National Registry of Myocardial
Infarction-2 (8,21,22). By providing hemodynamic support,
the pVAD enabled ICM patients with SRCS to be bridged
to definitive treatment. Despite the delay in revasculariza-
tion because of persistent shock, the ICM patients who
underwent revascularization after pVAD placement had a
50% mortality rate at 6 months, similar to that of their
Univariate Analysis of Pre-LVAD ValuesBetween Survivors and NonsurvivorsTable 7 Univari te Analysis of Pr -LVAD ValuesBetween Survivors and Nonsurvivors
Parameter p Value
Age 0.013
pH 0.479
BUN 0.513
PCWP 0.077
Pulmonary arterial pressure 0.195
EF 0.827
Pressors 0.137
Platelets 0.237
Hemoglobin 0.337
D-dimer 0.550
SVO2 0.95
EF 0.269
Mean arterial pressure 0.837
Cardiac index 0.437
Urine output 0.161
Creatinine 0.259
Hemoglobin 0.236
LDH 0.40
AST 0.014
ALT 0.03
Lactic acid 0.136
Abbreviations as in Table 3.SHOCK trial counterparts (8,23,24).The pVAD was also effective in providing hemodynamic
support to our NICM patients with SRCS. Like the ICM
group, these patients had worse baseline hemodynamic
values despite IABP and pressor support. The relatively
lower in-hospital mortality seen in the NICM group (32%
at 30 days) likely reflects both the younger age of these
patients relative to the ICM group (41.1  14.8 years vs.
61.8  11.0 years, p  0.001) and the lower incidence of
nderlying comorbidities.
Previous reports have shown the usefulness of the
andemHeart in stabilizing patients with cardiogenic
hock. We have reported earlier our initial experience
ith the TandemHeart pVAD in 11 patients with ICM
r NICM and cardiogenic shock with an initial cardiac
ndex of 1.57  0.3 l/(min·m2) (25). Thiele et al. (16)
eported an initial cardiac index of 1.7  0.3 l/(min·m2)
n their experience with the TandemHeart in 18 consecutive
atients who experienced cardiogenic shock after an acute
yocardial infarction. Compared with Thiele’s group, our
CM group was sicker and subsequently had a higher
ortality rate (50% vs. 43%) (16,25).
In our analysis of survivors versus nonsurvivors, the cause
f death was either superimposed infection or irreversible
nd-organ damage and subsequent multisystem organ fail-
re. Of the 21 patients who did not receive an IABP before
VAD placement, 15 (71%; 9 ICM and 6 NICM) were
live at 6 months despite undergoing CPR at the time of
evice placement. Twenty-four of the 56 patients (43%)
ith SRCS who underwent pVAD placement while under-
oing active CPR survived for at least 30 days; this fact
llustrates the efficacy of the pVAD in reestablishing end-
rgan perfusion and again suggests that earlier placement
ight have further decreased the total mortality rate.
Early in our experience with the pVAD, 1 device-related
eath resulted from wire-mediated left atrial perforation. In
omparison with previous pVAD series by Thiele et al. (16),
urs had a lower incidence of blood loss requiring transfu-
ion (71 of 117 [60%] vs. 19 of 21 [91%]) and a lower
ncidence of device-related limb ischemia (4 of 117 [3.4%]
s. 7 of 21 [33%]) (26). The low rate of limb complications
ay be due to routine use of peripheral angiography before
annula selection in our study, and a low threshold for
lacing an additional ante grade cannula for distal perfusion
f the limb (16,26). The relatively higher incidence of
acteremia could be influenced by the large number of
Multivariate Analysis of Survivors and NonsurvivorsTable 8 Multivariate Analysis of Survivors and Nonsurvivors
Hazard Ratio 95% CI p Value
Age 1.035 0.995–1.076 0.085
IABP 1.028 0.20–5.24 0.974
CPR 4.54 1.61–14.28 0.004
Pressors 1.14 0.76–1.71 0.513
MAP 1.00 0.97–1.02 0.985
Creatinine 1.35 0.86–2.12 0.192CI  confidence interval; MAP  mean arterial pressure; other abbreviations as in Table 5.
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sterile conditions did not exist during emergent line place-
ment, as well as the high number of peripheral catheters
associated with monitoring these patients.
Conclusions
The spectrum of cardiogenic shock ranges from moderate
hypoperfusion to terminal circulatory collapse and is associated
with considerable mortality. Although IABP counterpulsation
may provide adequate support for moderate cardiogenic shock,
more severe shock has traditionally required surgically im-
planted devices associated with significant death and morbid-
ity. However, in high-risk patients, the pVAD now bridges
that gap and provides an additional means of hemodynamic
support. The TandemHeart is an effective treatment option for
rapidly reversing terminal circulatory collapse and is associated
with less device-associated morbidity and mortality. Further
prospective randomized trials are warranted to evaluate the
efficacy of early pVAD placement in SRCS patients, though
these are very difficult to conduct in patients with cardiogenic
shock. A more thorough understanding of the full spectrum of
cardiogenic shock is needed to tailor therapy and improve
outcomes.
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